Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
Bailey TS, Takács R, Tinahones FJ, Rao PV, Tsoukas GM, Thomsen AB, Kaltoft MS, Maislos M. Bailey TS, et al. Among authors: tinahones fj. Diabetes Obes Metab. 2016 Dec;18(12):1191-1198. doi: 10.1111/dom.12736. Epub 2016 Sep 14. Diabetes Obes Metab. 2016. PMID: 27381275 Free PMC article. Clinical Trial.
Carbohydrate metabolism improvement after Helicobacter pylori eradication.
Roca-Rodríguez MM, Coín-Aragüez L, Cornejo-Pareja I, Alcaide J, Clu-Fernández C, Muñoz-Garach A, Durán-Martín E, Mora-Navas L, Gómez-Pérez AM, Molina-Vega M, Díaz-Perdigones C, Mancha-Doblas I, Tinahones FJ. Roca-Rodríguez MM, et al. Among authors: tinahones fj. Diabetes Metab. 2016 Apr;42(2):130-4. doi: 10.1016/j.diabet.2015.11.003. Epub 2015 Dec 23. Diabetes Metab. 2016. PMID: 26712113 No abstract available.
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Letierce A, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Cariou B, et al. Among authors: tinahones fj. Diabetes Metab. 2017 Oct;43(5):453-459. doi: 10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24. Diabetes Metab. 2017. PMID: 28347654 Free article. Clinical Trial.
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors. von Herrath M, et al. Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1. Lancet Diabetes Endocrinol. 2021. PMID: 33662334 Clinical Trial.
[Liraglutide in polycystic ovary syndrome].
Gómez-Pérez AM, Fernández-García JC, Mancha Doblas I, Tinahones FJ. Gómez-Pérez AM, et al. Among authors: tinahones fj. Med Clin (Barc). 2014 Sep 15;143(6):283-4. doi: 10.1016/j.medcli.2013.11.016. Epub 2014 Jan 21. Med Clin (Barc). 2014. PMID: 24456922 Spanish. No abstract available.
544 results